TargetBeta
TSHR
thyroid stimulating hormone receptor · also LGR3 · Glycoprotein hormone receptors
2 programs in company-led studies act on TSHR, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| IBI3031rule | Innovent Biologics | phase 1 | 11 running | IGF1R | the studies' text |
| REGN24493rule | Regeneron Pharmaceuticals | phase 1 | 11 running | – | the studies' text |
Also acted on by the same programs
Conditions their studies are in
- Graves Disease, 1 program
- Graves Ophthalmopathy, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jun 15, 2027IBI3031 · Innovent Biologics · phase 1 · NCT07622368
- Jan 28, 2030REGN24493 · Regeneron Pharmaceuticals · phase 1 · NCT07861152
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.